Neutralizing and binding antibodies to ifn-β: Relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-β preparations

Carolina Scagnolari, Giordano Dicuonzo, Guido Antonelli, Francesca Bellomi, Ombretta Turriziani, Francesca Bagnato, Valentina Tomassini, Vito Lavolpe, Marilena Ruggieri, Fabrizio Bruschi, Giuseppe Meucci

Research output: Contribution to journalArticlepeer-review

Abstract

The frequencies of anti-interferon-β (IFN-β) antibody development reported to date in patients treated with different IFN-β preparations are not readily comparable mainly because of differences in underlying diseases and assay methods. Thus, the frequency of neutralizing antibody (NAb) and binding antibody (BAb) development was analyzed in a sample of sera derived from a homogeneous group of relapsing-remitting multiple sclerosis (RRMS) patients treated with different IFN-β preparations. The frequency of developing NAb and BAb to IFN-β varied according to the IFN-β given. Specifically, the NAb seroconversion frequency was significantly higher in patients treated with Betaferon, Schering AG, Berlin, Germany (31.3%) than in patients treated with both preparations of recombinant IFN-β1a (Rebif, Serono, Geneva, Switzerland [7.4%] or Avonex, Biogen, Cambridge, MA [6.3%]). Analysis of BAb seroconversion frequency in the same patients revealed that different IFN-β preparations may also have different capability to induce BAb development and that BAb are produced during IFN-β therapy at a significantly higher rate than NAb. Our main conclusion is that different human IFN-β preparations may possess different immunogenicities, leading to varying frequency of development of antibody to IFN-β in RRMS.

Original languageEnglish
Pages (from-to)207-213
Number of pages7
JournalJournal of Interferon and Cytokine Research
Volume22
Issue number2
DOIs
Publication statusPublished - 2002

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Cell Biology

Fingerprint Dive into the research topics of 'Neutralizing and binding antibodies to ifn-β: Relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-β preparations'. Together they form a unique fingerprint.

Cite this